Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VeradigmSTU:AL21 17 EBITDA Margin % is 9.94% as of Dec. 2022. GuruFocus rates STU:AL21 with a GF Score™ of 17/100. Among 664 Healthcare Providers & Services companies, Veradigm ranks worse than 150602.26% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Veradigm's EBITDA for the
six
months ended in Dec. 2022 was €55.2 Mil. Veradigm's Revenue for the
six
months ended in Dec. 2022 was €555.1 Mil. Therefore, Veradigm's EBITDA margin for the quarter that ended in Dec. 2022 was 9.94%.
Veradigm (STU:AL21) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Veradigm EBITDA Margin % Related Terms
Veradigm EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Veradigm's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AL21 vs CTEV, EVH, PHR: EBITDA Margin % Comparison
For the Health Information Services subindustry, Veradigm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veradigm EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Veradigm's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veradigm (STU:AL21) has a EBITDA Margin % of 9.94% as of Dec. 2022. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 664 companies in the Healthcare Providers & Services industry.
Is Veradigm's EBITDA Margin % too high?
Veradigm's current EBITDA Margin % is 9.94%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Veradigm's value of 9.94% is 2.9% below this industry median. Based on the distribution chart, Veradigm ranks #999999 out of 664 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's EBITDA Margin % compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 664 companies for EBITDA Margin %. This places Veradigm in the lower half of its industry. The industry median EBITDA Margin % is 10.24. Veradigm's value of 9.94% is 2.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veradigm's current EBITDA Margin % of 9.94% is 2.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Veradigm and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veradigm's current EBITDA Margin % is 9.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current EBITDA Margin % of 9.94%. The current EBITDA Margin % is 9.94% and 2.9% below the Healthcare Providers & Services industry median of 10.24. Veradigm's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Veradigm (STU:AL21), the current EBITDA Margin % is 9.94% as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
17GF Score
Get the complete analysis for STU:AL21
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AL21 has been successfully added to your 
